Fisher Asset Management LLC Has $60.92 Million Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Fisher Asset Management LLC grew its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 47.4% during the fourth quarter, Holdings Channel.com reports. The firm owned 183,353 shares of the company’s stock after buying an additional 58,954 shares during the period. Fisher Asset Management LLC’s holdings in Medpace were worth $60,916,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in MEDP. Proficio Capital Partners LLC increased its holdings in shares of Medpace by 34,497.4% in the 4th quarter. Proficio Capital Partners LLC now owns 242,528 shares of the company’s stock valued at $80,575,000 after purchasing an additional 241,827 shares during the period. Iron Triangle Partners LP acquired a new position in shares of Medpace in the 3rd quarter valued at about $64,371,000. GW&K Investment Management LLC increased its holdings in shares of Medpace by 93.9% in the 4th quarter. GW&K Investment Management LLC now owns 275,460 shares of the company’s stock valued at $91,516,000 after purchasing an additional 133,379 shares during the period. Wellington Management Group LLP increased its holdings in shares of Medpace by 36.0% in the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after purchasing an additional 109,886 shares during the period. Finally, DF Dent & Co. Inc. increased its holdings in shares of Medpace by 189.9% in the 3rd quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company’s stock valued at $53,841,000 after purchasing an additional 105,659 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Robert W. Baird upped their target price on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $381.44.

Medpace Stock Performance

NASDAQ:MEDP opened at $327.32 on Friday. The stock’s 50 day moving average price is $342.66 and its 200 day moving average price is $345.44. Medpace Holdings, Inc. has a 52 week low of $302.01 and a 52 week high of $459.77. The company has a market capitalization of $9.97 billion, a P/E ratio of 25.92, a P/E/G ratio of 3.81 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.